US Day 13 #Earnings
今回のEarningsの共通した事項
経営陣が供給不足の終わりを予想できない中、2022年上半期にも終わらないという意見が大勢だ。 それにより、Guidence 未提示 or 下方が行われる中
XOM Earnings Beat. RevよりEPSが重要な時点。 理由はESGなどによるOil関連企業への全面的なプレッシャーのためだ。 元々Value Stockの性格を帯びていたが、さらにCashflowが重要になっており、DCFへのアクセスを非常にお勧め。 したがって、総合的にはEarnings Beatだが、肯定的により近い。
CVX Consensus 上回る。 他に内容はない。
ABBVConsensusを上回り配当$1.30→$1.41に引き上げ、ガイダンスも上方修正。 4.5%上昇、DivYieldは約4.5%→4.9%、これはPFE3.57%、JNJ2.60%、MRK2.95%、GILD4.38%よりも高い数値。 大手製薬会社の中で配当収益率が最も高い。
LHX Day 10 参考。 流れはSector全体と似ている。 (Defense)
PSX Articleに置き換え
https://www.reuters.com/article/phillips-66-results/phillips-66-profit-blasts-past-estimates-on-refining-margins-boost-idUSKBN2HJ1EP?theme=0&color=2
XOM, CVX, PSXは月曜日にうんざりするほど
US Day 13 #Earnings
Common points of Earnings.
MGMT is not expecting an end to the supply shortage. It is widely believed that it will not end in the first half of 2022. Accordingly, guidance is not presented or lowered.
XOM
Earnings Beat. When EPS is more important than Rev. The reason is the omnidirectional pressure on oil-related companies due to ESG. Originally, it had a value stock character, but Cashflow is becoming more important. It is highly recommended to approach DCF. Therefore, overall, it is Earnings Beat, but it is closer to positive.
CVX
It exceeded Consensus. There's nothing special.
ABBV
Consensus trading and dividend increase to $1.30 -> $1.41 and guidance increase to 4.5%, Div Yield about 4.5% -> 4.9%, which is higher than PFE 3.57%, JNJ 2.60%, MRK 2.95%, and GILD 4.38%. It has the highest dividend yield among large pharmaceutical companies.
LHX
Refer to Day 10. The flow is similar to the entire Sector. (Defense)
PSX
Replace it with an art.
https://www.reuters.com/article/phillips-66-results/phillips-66-profit-blasts-past-estimates-on-refining-margins-boost-idUSKBN2HJ1EP?theme=0&color=2
XOM, CVX, PSX should watch the flow on Monday.
English Channel
Japanese Channel